Infectious Disease Advisor news story
Among individuals with HIV at low to moderate risk for atherosclerotic cardiovascular disease, pitavastatin use is associated with a reduced incidence of hypertension and lower subsequent cardiovascular risk, according to study findings published in The Lancet HIV.
Researchers performed a prespecified secondary analysis of REPRIEVE (ClinicalTrials.gov Identifier: NCT02344290), a global randomized, double-blind, placebo-controlled trial evaluating pitavastatin for primary cardiovascular prevention in individuals with HIV. They assessed whether pitavastatin lowered the risk for incident hypertension and whether new-onset hypertension was associated with major adverse cardiovascular events. The analysis included adults aged 40 to 75 years receiving stable antiretroviral therapy who had low to moderate atherosclerotic cardiovascular disease risk.
Read the full news story here.
/Infectious Disease Advisor requires free registration if more than 5 articles are viewed per month/
Source : Infectious Disease Advisor
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.